Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

Clonal haematopoiesis of indeterminate potential and incident cardiovascular disease in individuals with MASLD

5 affiliations
  1. 1Department of Health Management Centre, The Eighth Affiliated Hospital of Southern Medical University (The First People's Hospital of Shunde)
  2. 2Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine
  3. 3Department of Endocrinology and Metabolism, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences
  4. 4Department of Endocrinology and Metabolism, The Eighth Affiliated Hospital of Southern Medical University (The First People's Hospital of Shunde)
  5. 5Guangdong Engineering Technology Research Center of Metabolic Disorders Interdisciplinary Precision Prevention and Digital Healthcare, The Eighth Affiliated Hospital of Southern Medical University (The First People's Hospital of Shunde)

Abstract

Background: The impact of clonal haematopoiesis of indeterminate potential (CHIP), a novel cardiovascular risk factor, remains unclear in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), where cardiovascular disease (CVD) is the main cause of mortality.

Methods: We analysed data from 140,086 UK Biobank participants with MASLD. CHIP was identified via whole-exome sequencing. Incident CVD, including coronary heart disease (CHD), stroke, and heart failure (HF), was the primary outcome. Cox proportional hazards models assessed the association between CHIP and CVD risk.

Results: During a median 13.5-year follow-up, 15.7% of participants developed CVD. CHIP was associated with a higher risk of CVD (HR: 1.16, 95% CI: 1.09–1.23), with higher risks of stroke (HR: 1.22, 95% CI: 1.07–1.38) and HF (HR: 1.34, 95% CI: 1.21–1.49). Mutations in ASXL1, SRSF2, JAK2 , and SF3B1 were associated with a particularly high CVD risk. Additionally, a higher clonal haematopoiesis risk score (CHRS) was associated with incident CVD, CHD, stroke, and HF. In the three-category analysis, the P value for trend was significant for all outcomes, but the association was confined to large CHIP for CVD and CHD, whereas both CHIP categories showed elevated estimates for stroke and HF.

Conclusions: CHIP is independently associated with incident CVD in patients with MASLD. These findings support prospective evaluation of CHIP-informed cardiovascular risk stratification in this population.

Related

  1. Clonal haematopoiesis of indeterminate potential and postoperative neuroinflammation in cardiac surgery: a hypothesis-generating review
    Aleksei Furgal, Iakov Samushya, Oleg Pak +1
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefDOAJ
  2. Association of clonal hematopoiesis of indeterminate potential with cardiovascular mortality in cardiovascular-kidney-metabolic syndrome: a large prospective cohort study.
    Zehao Zhao, Changsheng Ma, Libo Zhao +10
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMCCrossref
  3. Visceral adipose tissue and incident cardiovascular disease among individuals without diabetes: an analysis of 15 prospective cohorts from 7 countries in Latin America
    Mario Cesar Torres-Chavez, Jesus Ernesto Martinez-Luna, Maria Fernanda Suarez-Velazquez +99
    The Lancet Regional Health - AmericasPeer-reviewedCC BY-NCGeneral biologyEpidemiology & public healthHAL
  4. Joint association of five insulin resistance indices and frailty index with incident cardiometabolic multimorbidity in individuals with cardiovascular–kidney–metabolic syndrome stages 0–3: a prospective cohort study
    Jiawang Zou, Hailan Xiong, Shuchang Ding +6
    Cardiovascular DiabetologyPeer-reviewedCC BY-NC-ND 4.0Full textEndocrinology & metabolismPMC
  5. Clonal Hematopoiesis of Indeterminate Potential and Bone Mineral Density in Cohorts from Trans-Omics for Precision Medicine
    Douglas P. Kiel, Wingel Xue, Hanfei Xu +10
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchPeer-reviewedLicence not statedFull textSurgery & anaesthesiaPMC
BibTeX
@article{lin2026clonal,
  title = {{Clonal haematopoiesis of indeterminate potential and incident cardiovascular disease in individuals with MASLD}},
  author = {Yijun Lin and Qianyun Wang and Ying Sun and Yuefeng Yu and Yingwen Nie and Keyue Yang and Ningjian Wang and Heng Wan and Feng Tian},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = nov,
  doi = {10.3389/fcvm.2026.1998218},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1998218/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Clonal haematopoiesis of indeterminate potential and incident cardiovascular disease in individuals with MASLD
AU  - Yijun Lin
AU  - Qianyun Wang
AU  - Ying Sun
AU  - Yuefeng Yu
AU  - Yingwen Nie
AU  - Keyue Yang
AU  - Ningjian Wang
AU  - Heng Wan
AU  - Feng Tian
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1998218
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1998218/full
AB  - Background: The impact of clonal haematopoiesis of indeterminate potential (CHIP), a novel cardiovascular risk factor, remains unclear in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), where cardiovascular disease (CVD) is the main cause of mortality.  Methods: We analysed data from 140,086 UK Biobank participants with MASLD. CHIP was identified via whole-exome sequencing. Incident CVD, including coronary heart disease (CHD), stroke, and heart failure (HF), was the primary outcome. Cox proportional hazards models assessed the association between CHIP and CVD risk.  Results: During a median 13.5-year follow-up, 15.7% of participants developed CVD. CHIP was associated with a higher risk of CVD (HR: 1.16, 95% CI: 1.09–1.23), with higher risks of stroke (HR: 1.22, 95% CI: 1.07–1.38) and HF (HR: 1.34, 95% CI: 1.21–1.49). Mutations in ASXL1, SRSF2, JAK2 , and SF3B1 were associated with a particularly high CVD risk. Additionally, a higher clonal haematopoiesis risk score (CHRS) was associated with incident CVD, CHD, stroke, and HF. In the three-category analysis, the P value for trend was significant for all outcomes, but the association was confined to large CHIP for CVD and CHD, whereas both CHIP categories showed elevated estimates for stroke and HF.  Conclusions: CHIP is independently associated with incident CVD in patients with MASLD. These findings support prospective evaluation of CHIP-informed cardiovascular risk stratification in this population.
SN  - 2297-055X
ER  -